Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs ↗

February 24, 2025

Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities.

Via Benzinga

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

February 24, 2025

CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment.

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride ↗

February 18, 2025

Via Stocktwits

Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock ↗

February 10, 2025

Via Benzinga

12 Analysts Have This To Say About Axsome Therapeutics ↗

January 21, 2025

Via Benzinga

Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts ↗

December 30, 2024

Via Benzinga

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗

February 18, 2025

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday.

Via Benzinga

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Via Benzinga

Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript ↗

February 18, 2025

AXSM earnings call for the period ending December 31, 2024.

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated losses.

Topics Earnings

Axsome Therapeutics Revenue Surges 66% ↗

February 18, 2025

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 18, 2025

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? ↗

February 16, 2025

Earnings Scheduled For February 18, 2025 ↗

February 18, 2025

Via Benzinga

Why Axsome Therapeutics Stock Is Soaring Today ↗

February 11, 2025

Why Axsome Therapeutics Stock Is Skyrocketing Today ↗

February 10, 2025

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗

February 10, 2025

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Via Benzinga

Topics Intellectual Property

Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday ↗

February 10, 2025

Via Benzinga

Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells ↗

February 10, 2025

Under the settlement terms, Teva will receive a license to sell a generic version of Auvelity starting March 31, 2039, if pediatric exclusivity is granted.

Via Stocktwits

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

February 10, 2025

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

January 31, 2025

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

January 30, 2025

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

January 22, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Via Investor's Business Daily

Topics Economy

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

January 13, 2025

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗

December 31, 2024

Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.

Via Benzinga

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation ↗

December 30, 2024

Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Via Investor's Business Daily

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 30, 2024

Via Benzinga

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

December 30, 2024